Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 4 of the 66 sources its claims cite were checked for support.
Abstract
BACKGROUND: A three-pronged approach to acne treatment-combining an antibiotic, antibacterial, and retinoid-could provide greater efficacy and tolerability than single or dyad treatments, while potentially improving patient compliance and reducing antibiotic resistance. OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne. METHODS: In a phase II, double-blind, multicenter, randomized, 12-week study, eligible participants aged ≥ 9 years with moderate-to-severe acne were equally randomized to once-daily IDP-126, vehicle, or one of three component dyad gels: BPO/adapalene; clindamycin phosphate/BPO; or clindamycin phosphate/adapalene. Coprimary endpoints were treatment success at week 12 (participants achieving a ≥ 2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin) and least-squares mean absolute changes from baseline in inflammatory and noninflammatory lesion counts to week 12. Treatment-emergent adverse events and cutaneous safety/tolerability were also assessed. RESULTS: A total of 741 participants were enrolled. At week 12, 52.5% of participants achieved treatment success with IDP-126 vs vehicle (8.1%) and dyads (range 27.8-30.5%; P ≤ 0.001, all). IDP-126 also provided significantly greater absolute reductions in inflammatory (29.9) and noninflammatory (35.5) lesions compared with vehicle or dyads (range inflammatory, 19.6-26.8; noninflammatory, 21.8-30.0; P < 0.05, all), corresponding to > 70% reductions with IDP-126. IDP-126 was well tolerated, with most treatment-emergent adverse events of mild-to-moderate severity. CONCLUSIONS: Once-daily treatment with the novel fixed-dose triple-combination clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% gel demonstrated superior efficacy to vehicle and all three dyad component gels, and was well tolerated over 12 weeks in pediatric, adolescent, and adult participants with moderate-to-severe acne. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03170388 (registered 31 May, 2017).
Overview
CoChat Summary
TL;DR
In a phase II, double-blind, randomized, 12-week trial, fixed-dose clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel (IDP-126) was superior to vehicle and all three component dyad gels for moderate-to-severe acne. IDP-126 was well tolerated, with most treatment-emergent adverse events mild to moderate.
Key findings
- At week 12, 52.5% of IDP-126-treated participants achieved treatment success versus 8.1% with vehicle and 27.8–30.5% with the three dyad gels (P ≤ 0.001 for all comparisons).
- IDP-126 produced greater absolute reductions from baseline in inflammatory lesions (29.9) and noninflammatory lesions (35.5) than vehicle or dyads (inflammatory range 19.6–26.8; noninflammatory range 21.8–30.0; P < 0.05 for all), corresponding to >70% reductions.
- Treatment-emergent adverse events were mostly mild or moderate; discontinuations due to treatment-emergent adverse events occurred in 0–5.3% across treatments, with the highest rate in the BPO/adapalene group.
- Four participants had one serious adverse event each, none considered related to treatment.
Methods
- Phase II, multicenter, randomized, double-blind, parallel-group, vehicle-controlled study at 31 US and 4 Canadian centers; participants aged ≥9 years with moderate (EGSS 3) or severe (EGSS 4) acne were equally randomized to once-daily IDP-126, vehicle, or one of three component dyad gels for 12 weeks.
- Coprimary endpoints were treatment success at week 12 (≥2-grade EGSS reduction plus clear/almost clear) and absolute changes from baseline to week 12 in inflammatory and noninflammatory lesion counts.
- Treatment success used logistic regression; lesion count changes used rank-transformed ANCOVA with multiple imputation for missing efficacy data; 741 participants were randomized, 740 were in the intent-to-treat population, and 725 were in the safety population.
Limitations
- The paper states that EGSS assessments may have inter-observer bias or variation, treatment duration was limited to 12 weeks, and results may not be generalizable to diverse real-world practice populations differing in race, age, and sex.
- The paper states that exclusion of component monads prevented determination of each active treatment’s direct contribution and calculation of synergistic treatment effect.
- The paper states that no head-to-head or facial-splitting studies were conducted against other approved dyad treatments, and no formal sample size calculation was performed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Least-squares (LS) mean percent reductions in a inflammatory lesions and b noninflammatory lesions (intent-to-treat [ITT] population). Multiple imputation was used to impute missing values. *P < 0.05; ***P < 0.001 vehicle vs clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126). Data not shown: P-values for IDP-126 vs dyads were significant (P < 0.05) as follows: inflammatory lesions: benzoyl peroxide 3.1%, (BPO)/adapalene 0.15% (ADAP) at weeks 2, 4, 8, and 12; clindamycin phosphate 1.2%, (CLIN)/BPO at weeks 4 and 12; CLIN/ADAP at weeks 4, 8, and 12. Noninflammatory lesions: BPO/ADAP at weeks 8 and 12; CLIN/BPO at weeks and weeks 4, 8, and 12; CLIN/ADAP at weeks 4, 8, and 12. All active dyad treatments were significant vs vehicle at weeks 8 and 12 for both inflammatory and noninflammatory lesions (P < 0.01, all); additionally, CLIN/BPO and CLIN/ADAP were significant vs vehicle at weeks 2 and 4 for inflammatory lesions (P < 0.05, all) and BPO/ADAP and CLIN/ADAP were significant vs vehicle at week 4 for noninflammatory lesions (P < 0.01, both)](https://figures.cochat.ai/paper-figures/407c1a278aa04cce83a4e056cd3b944e/efficacy-and-safety-of-a-fixed-dose-clindamycin-phosphate-1-2-benzoyl-peroxide-3-figure-2.jpg)


Verification
Claims the paper makes
3 Valid · 1 Not valid · 31 Not checked · 82 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This rationale is supported by a meta-analysis that showed clindamycin combined with BPO had lower odds of patient withdrawal/discontinuation because of AEs than BPO alone or BPO/adapalene combinations [14].”
§ Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug > Discussion
What the sources say
- Disputedcites [14] Stuart B, Maund E, Wilcox C, Sridharan K, Sivaramakrishnan G, Regas C, et al. Topical preparations for the treatment of mild-to-moderate acne vulgaris: systematic review and network meta-analysis. Br J Dermatol. 2021;185(3):512–25. sourceExperimental — accuracy not yet measured
The Summary (p. 1) reports a higher withdrawal rate for clindamycin + BPO (2.7%) than for BPO alone (1.6%), contrary to the claimed lower odds versus BPO. The Adverse events section (p. 7) ranks adapalene + BPO highest for withdrawal, so the direction of that comparison is consistent with the claim, but the BPO-alone comparison is not. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“irritation may be an issue with certain combinations [11–14].”
§ Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug > Introduction
What the sources say
- Not checked yetcites [11] Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg. 2001;5(1):37–42. source
- Not checked yetcites [12] Tschen EH, Katz HI, Jones TM, Monroe EW, Kraus SJ, Connolly MA, et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis. 2001;67(2):165–9.
- Not checked yetcites [13] Gold LS, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84(2):110–6.
- Partly supportedcites [14] Stuart B, Maund E, Wilcox C, Sridharan K, Sivaramakrishnan G, Regas C, et al. Topical preparations for the treatment of mild-to-moderate acne vulgaris: systematic review and network meta-analysis. Br J Dermatol. 2021;185(3):512–25. sourceExperimental — accuracy not yet measured
Our copy supports the dyad-level harm signal only through withdrawal/discontinuation: the Summary (p. 1) reports withdrawal rates slightly higher for BPO with adapalene (2.5%) or clindamycin (2.7%) than BPO (1.6%) or adapalene alone (1.0%), and Adverse events (p. 7) gives adapalene + BPO the highest odds of withdrawal (OR 4.35, 95% CI 2.13-9.09), with clindamycin + BPO also above clindamycin alone; 'What does this study add?' (p. 2) hedges this as combination adapalene + BPO 'may cause more adverse events'. However, the specific endpoint the claim names — irritation — is not what this review measured: the Discussion (p. 11) states adverse event data were poorly reported, that they 'were not able to compare adverse events that may concern patients starting a new treatment regimen, such as stinging, itching or peeling', and mentions redness/peeling only as a blinding caveat. So the source supports increased adverse events/withdrawal with these BPO dyads, but 'irritation' rests on discontinuation as a proxy rather than on measured irritation rates. (LLM, conf=0.72)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Adherence rates to oral or topical acne treatments, however, are typically poor and reasons for low adherence include complex regimens, lack of efficacy, and adverse effects [3, 4].”
§ Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug > Introduction
What the sources say
- Not checked yetcites [3] Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14. source
- Supportedcites [4] Moradi Tuchayi S, Alexander TM, Nadkarni A, Feldman SR. Interventions to increase adherence to acne treatment. Patient Prefer Adherence. 2016;10:2091–6. source
The Introduction says adherence to even simple acne regimens is poor, and the Conclusion states that acne medication adherence is poor. The Discussion identifies complex regimens, poor efficacy, and adverse effects as reasons for lower adherence, including for topical and oral treatments. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Regimens with side effects, low efficacy, or high complexity (e.g., using several treatments at one time, taking multiple doses in a day) can adversely affect treatment adherence [3, 4].”
§ Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug > Discussion
What the sources say
- Not checked yetcites [3] Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14. source
- Supportedcites [4] Moradi Tuchayi S, Alexander TM, Nadkarni A, Feldman SR. Interventions to increase adherence to acne treatment. Patient Prefer Adherence. 2016;10:2091–6. source
The Results section identifies lack of efficacy, complicated regimens, and adverse reactions as hurdles to acne treatment adherence. The Discussion also says that moving from one treatment to multiple treatments leads to less adherence. No page numbers are available in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Discontinuations because of TEAEs were highest in the BPO/adapalene group (Table 3).”
§ Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug > Results > Safety
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
58 more claims
Create a free account to see all 117 claims and to verify the 62 references still open.
- The quote only partly states this claim. 5
- Probably not a substantial claim. 36
- It may state two separate claims as one. 27
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Greater reductions in both inflammatory (MD in the percentage change from baseline, À37.34% [À72.49%,À2.18%]) and noninflammatory (MD, À20.47% [À26.31,À14.62]) lesion counts were seen in combined BP and topical antibiotic versus vehicle at 12 weeks in 4 RCTs.66,69,99,101”
From Guidelines of care for the management of acne vulgaris (2024) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“Greater reductions in both inflammatory (MD in the percentage change from baseline, À37.34% [À72.49%,À2.18%]) and noninflammatory (MD, À20.47% [À26.31,À14.62]) lesion counts were seen in combined BP and topical antibiotic versus vehicle at 12 weeks in 4 RCTs.66,69,99,101”
From Guidelines of care for the management of acne vulgaris (2024) · cites this paper as [99]
Experimental — accuracy not yet measured
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Medication Adherence: WHO Cares?
Brown, M. T., & Bussell, J. K. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0575 · Cited by 1,928
Guidelines of care for the management of acne vulgaris
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.037 · Cited by 1,597
Self-citationThiboutot, D. M., Weiss, J., Bucko, A., Eichenfield, L., Jones, T., Clark, S., Liu, Y., Graeber, M., & Kang, S. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.06.006 · Cited by 183
Self-citationWhy Topical Retinoids Are Mainstay of Therapy for Acne
Leyden, J., Stein-Gold, L., & Weiss, J. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0185-2 · Cited by 164
Self-citationMartin, A. R., Lookingbill, D. P., Botek, A., Light, J., Thiboutot, D., & Girman, C. J. (2001) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2001.00839.x · Cited by 157
Pharmacology and chemistry of adapalene
Shroot, B., & Michel, S. (1997) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(97)70050-1 · Cited by 140
Thiboutot, D., Zaenglein, A., Weiss, J., Webster, G., Calvarese, B., & Chen, D. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.06.040 · Cited by 99
Self-citation(2010) · PubMed · Cited by 93
Antibiotic resistance in acne: changes, consequences and concerns
Karadag, A. S., Aslan Kayıran, M., Wu, C. ‐., Chen, W., & Parish, L. C. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16686 · Cited by 91
Cited by
Guidelines of care for the management of acne vulgaris
Reynolds, R. V., Yeung, H., Cheng, C. E., Cook-Bolden, F., Desai, S. R., Druby, K. M., Freeman, E. E., Keri, J. E., Stein Gold, L. F., Tan, J. K. L., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.12.017 · Cited by 518
Self-citationAcne treatment review and future perspectives
Mohsin, N., Hernandez, L. E. D. L. C., Martin, M. R., Does, A. V., & Nouri, K. (2022) · Dermatologic Therapy · doi:10.1111/dth.15719 · Cited by 92
Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease
Armillei, M. K., Lomakin, I. B., Rosso, J. Q. D., Grada, A. A., & Bunick, C. G. (2024) · Antibiotics · doi:10.3390/antibiotics13030270 · Cited by 44
New Developments in Topical Acne Therapy
Drake, L., Reyes-Hadsall, S., Barbieri, J. S., & Mostaghimi, A. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00666-9 · Cited by 41
Huang, C., Chang, I.-J., Bolick, N. L., Hsu, W., Su, C., Hsieh, T., Huang, I.-H., & Lee, C. (2023) · The Annals of Family Medicine · doi:10.1370/afm.2995 · Cited by 39
Metadata
- Authors
- Stein Gold, L., Baldwin, H., Kircik, L. H., Weiss, J. S., Pariser, D. M., Callender, V., Lain, E., Gold, M., Beer, K., Draelos, Z., Sadick, N., Pillai, R., Bhatt, V., & Tanghetti, E. A.
- Affiliations
- Robert Wood Johnson University Hospital (US)
- Indiana University School of Medicine (US)
- Eastern Virginia Medical School (US)
- Howard University (US)
- Tennessee Clinical Research Center (US)
- University of Miami (US)
- Dermatology Consulting Services (US)
- Sadick Dermatology (US)
- Bausch Health (United States) (US)
- Center for Dermatology and Laser Surgery (US)
- ORCID
- Venue
- American Journal of Clinical Dermatology
- Published
- 2021-10-21
- Volume
- 23
- Issue
- 1
- Pages
- 93-104
- ISSN
- 1175-0561 (ISSN-L)
- 1179-1888
- PMC
- PMC8776677
- OpenAlex
- W3206427606
- Cited by
- 51
- References
- 31
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 15 · 2023: 6 · 2022: 6
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- American Journal of Clinical Dermatology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
- Funders
- Ortho Dermatologics
- Bausch Health
- Topics
- Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
- Keywords
- acne, clindamycin phosphate, benzoyl peroxide, adapalene, moderate to severe acne, safety and tolerability, antibiotic resistance, retinoids, antibacterial agents, medication adherence, pediatric acne
- MeSH terms
- Adapalene, Acne Vulgaris, Administration, Topical, Adolescent, Adult, Benzoyl Peroxide, Child, Clindamycin, Dermatologic Agents, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. https://app.cochat.ai/papers/10.1007/s40257-021-00650-3
- The paper
- Stein Gold, L., Baldwin, H., Kircik, L. H., Weiss, J. S., Pariser, D. M., Callender, V., Lain, E., Gold, M., Beer, K., Draelos, Z., Sadick, N., Pillai, R., Bhatt, V., & Tanghetti, E. A. (2022). Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-021-00650-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.